HLB's Innovative Hub & Spoke Model: Revolutionizing K-Bio Drug Development Strategies
AI 요약 정보
- HLB pursues asset-based Hub & Spoke drug development
- Each asset gets a team; HLB provides strategy and regulatory support
- Yang says K-bio firms need to lead late trials and approvals